Selecta Biosciences Inc (SELB.OQ)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|48||2017||Chairman of the Board|
|64||2017||President, Chief Executive Officer|
|45||2017||Chief Financial Officer, Principal Accounting Officer, Head of Corporate Strategy and Treasurer|
|49||Chief Operating Officer, Senior Vice President - Research & development|
|57||Chief Scientific Officer|
- BRIEF-Selecta Biosciences Announces Q1 Loss Per Share $0.71
- BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout
- BRIEF-Selecta Biosciences Qtrly Loss Per Share $0.88
- BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
- BRIEF-Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End